First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Concepedia

Concepedia

Publication | Open Access

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

DOI Full Paper Access

45

Citations

14

References

2024

Year

Christian Marth, Richard G. Moore, Mariusz Bidziński, Sandro Pignata, Ali̇ Ayhan, María Jesús Rubio, Mario Beiner, Marcia Hall, Christof Vulsteke, Elena Ioana Braicu,

Journal of Clinical Oncology

Abstract

First-line len + pembro did not meet prespecified statistical criteria for PFS or OS versus chemotherapy in pMMR aEC.

References

	Year	Citations

Page 1